Date of the CVA	15/06/2017

Section A. PERSONAL DATA

Name and Surname	David ARAUJO VILAR		
DNI	35291313k	Age	56
Researcher's identification number	Researcher ID		
	Código Orcid	orcid.org/0000-0003-2852-7851	

A.1. Current professional situation

Institution	Universidade de Santiago de Compostela			
Dpt. / Centre				
Address	UETEM-LAB 3, 2º planta, CIMUS, Avda Barcelona s/n, 15707, Santiago de Compostela			
Phone	639393458	Email	david.araujo@usc.es	
Professional category	Profesor Titular Numerario de Universidad		Start date	1998
UNESCO spec. code	320000 - Medical Science			
Keywords	Clinical medicine			

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Programa Oficial de Doctorado en Medicina	Universidad de Santiago de Compostela	1990
Licenciado en Medicina y Cirugía	MINISTERIO DE EDUCACION Y CIENCIA	1986

A.3. General quality indicators of scientific production

H-index: 15
H-index excluding self-citations: 13
Cumulated impact factor: 126,4
Total citations: 514

Section B. SUMMARY OF THE CURRICULUM

David Araújo-Vilar is a consultant physician in Endocrinology and Nutrition at the University Clinical Hospital of Santiago de Compostela (CHUS) and Associated Professor of Medicine (Profesor Titular de Universidad) at the School of Medicine of Santiago. Clinical and research postgraduate training was in Oxford University and in Santiago de Compostela General Hospital, including a PhD under the supervision of Prof. Cabezas-Cerrato investigating the mathematical modelling of glucose metabolism in diabetes mellitus and obesity. Over the past 10 years his clinical and research interests have centred on the genetic basis of rare lipodystrophic syndromes and severe insulin resistance syndromes. Relevant contributions include the description of Celia's encephalopathy or PELD (MIM: #615924), a new pediatric lipodystrophy-associated neurodegenerative syndrome (J Med Genet 2013) and its pathogenetic mechanisms (Neurobiol Dis 2015), and the identification of the pathogenesis of LMNA-associated familial partial lipodystrophy (J Med Genet 2009, http://omim.org/entry/151660). Lastly his research has particularly focused in the role of seipin in adipogenesis and neurodegeneration, the pathogenic mechanisms of lipodystrophic laminopathies, the search for new genes related to partial lipodystrophy, the effects of human recombinant leptin treatment on generalized lipodystrophies, and the clinical characterization of Köbberling Syndrome. He is the responsible physician of the Unit of Lipodystrophies at the Division of Endocrinology in the CHUS. It is the only Spanish centre currently permitted to treat patients with lipodystrophy with leptin therapy. He is the president of the Spanish Lipodystrophy Society and member of the Executive Board of the European Consortium of Lipodystrophies, which involves more than 30 european research groups devoted of rare lipodystrophic syndromes. Since 2014 he is member of the Experts Committee of the Spanish Federation of Rare Diseases. He has published more than 45 peer reviewed articles and his current H-index is 15.

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

1 **Scientific paper**. Elaine Chiquette; et al. (5/4). 2017. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Dove Press Ltd. 10, pp.1-9. ISSN 1178-7007.

2 **Scientific paper**. Y Tu; et al. (5/3). 2016. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.Nucleus. 7, pp.512-521.

3 **Scientific paper**. Sofia Sánchez Iglesias; et al. (10/10). 2016. Skipped BSCL2 Transcript in Celia's Encephalopathy (PELD): New Insights on Fatty Acids Involvement, Senescence and Adipogenesis.PLoS One. 11-e0158874.

4 **Scientific paper**. Rebecca Brown; et al. (17/2). 2016. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.J Clin Endocrinol Metab. 101, pp.4500-4511.

5 **Scientific paper**. Cristina Guillin Amarelle; et al. (11/11). 2016. Type 1 Familial Partial Lipodystrophy: Understanding the Köbberling Syndrome Endocrine.

6 **Scientific paper**. Alejandro Ruiz Riquelme; et al. (12/11). 2015. Larger aggregates of mutant seipin in Celia's Encephalopathy, a new protein misfolding neurodegenerative disease Neurobiol Dis.83, pp.44-53.

7 **Scientific paper**. David Araujo Vilar; et al. (13/1). 2015. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long- term Spanish experience Endocrine. 49-1, pp.139-147.

8 **Scientific paper**. Cristina Guillin Amarelle; Sofia Sánchez Iglesias; Corresponding author. (/3,3). 2015. Uncommon lipodystrophic syndromes Medicina Clinica (Barc.). 144-2, pp.80-87.

9 **Scientific paper**. ENCARNACION GUILLEN NAVARRO; et al. (/17,17). 2013. A new seipin-associated neurodegenerative syndrome Journal of Medical Genetics. 50-6, pp.401-409.

10 **Scientific paper**. David Araújo Vilar; et al. (/1,9). 2012. Histological and molecular features of lipomatous and non lipomatous adipose tissue from subjects with familial partial lipodystrophy due to LMNA mutations.Clinical Endocrinology. 76-6, pp.816-824.

11 **Scientific paper**. S Pajares; et al. (/10,19). 2010. Functional Consequences of Seven Novel Mutations in the CYP11B1 Gene: Four Mutations Associated with Nonclassic and Three Mutations Causing Classic 11{beta}-Hydroxylase Deficiency Journal of Clinical Endocrinology and Metabolism. 95-2, pp.779-788.

12 **Scientific paper**. Berta Victoria Martínez; et al. (/9,9). 2010. Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy Diabetic Medicine. 27, pp.1178-1187.

13 **Scientific paper**. Joaquín Lado Abeal; et al. (/6,6). 2010. Regional decrease of subcutaneous adipose tissue in patients with type 2 familial partial lipodystrophy is associated with changes in thyroid hormone metabolism Thyroid. 20-4, pp.419-424.

14 **Scientific paper**. David Araújo Vilar; et al. (/1,15). 2009. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.Journal of Medical Genetics. 46, pp.40-48.

15 **Scientific paper**. David Araújo Vilar; et al. (/1,13). 2008. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.Clinical Endocrinology. 69-1, pp.61-68.

16 **Scientific paper**. Fernando Palos; et al. (/7,17). 2008. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine deficient area in NW Spain.European J Endocrinol. 159, pp.623-31.

17 **Scientific paper**. Lourdes Loidi; et al. (/7,11). 2006. High variability in CYP21A2 mutated alleles in Spanish 21-hydroxylase deficiency patients, six novel mutations and a founder effect.Clinical Endocrinology. 64-3, pp.330-336.

18 **Scientific paper**. Isabelle Jéru; et al. (5/3). 2017. Clinical Utility Gene Card for: Familial partial lipodystrophy.Eur J Hum Genet. 25.

19 **Scientific paper**. R Panikkath; et al. (5/4). 2016. An Uncommon Association of Familial Partial Lipodystrophy, Dilated Cardiomyopathy, and Conduction System Disease.J Investig Med High Impact Case Rep. 15.
20 **Scientific paper**. I Jeru; et al. (5/3). 2016. Clinical Utility Gene Card for: Congenital Generalized Lipodystrophy Eur J Hum Genet.24.
21 **Scientific paper**. Ana Ramos Levi; et al. (/6,6). 2012. Axonal neuropathy, long limbs and bumpy tongue: Think of MEN2B Muscle&Nerve. 46, pp.961-964.
22 **Scientific paper**. Joaquín Lado Abeal; et al. (/3,1). 2011. Clinical and molecular study of five families with resistance to thyroid hormones.Medicina Clínica (Barc). 137-12, pp.551-554.
23 **Scientific paper**. Diego Peteiro; et al. (/4,4). 2011. Severe localized lipoatrophy related to therapy with insulin analogs in type 1a diabetes mellitus Diabetes Research and Clinical Practice. 91-3, pp.e61-e63.
24 **Scientific paper**. R Lago; et al. (/6,8). 2009. Prevalence and functional analysis of the S107P SNP (rs6647476) of the SLC16A2 gene in the male population of Northwest Spain (Galicia) Clinical Endocrinology. 70-4, pp.636-643.
25 **Scientific paper**. Lourdes Domínguez Gerpe; David Araújo Vilar. (/2,2). 2008. Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes Current Aging Science. 1, pp.202-212.

C.2. Participation in R&D and Innovation projects

1 European registry of Lipodystrophies University of Ulm. Martin Wabitsch. (University of Ulm). 03/10/2016-31/08/2021. 20.000 €.
2 Genomic England GeCIP Steve O'Rahilly. (University of Cambridge). 08/11/2016-30/10/2020. 1.000.000 €.
3 Historia natural, prevalencia y bases moleculares de la encefalopatía de Celia Fundación Mutua Madrileña. David Araujo Vilar. (CIMUS-USC). 01/09/2015-07/12/2018. 130.000 €. Principal investigator.
4 FPLD1 GWAS Replication Welcome Trust Sanger Institute. David Savage. (University of Cambridge). 13/12/2016-23/11/2018. 100.000 €.
5 BFU2015-70454-REDT, RED DE INVESTIGACION SOBRE PLASTICIDAD ADIPOSA Y SU IMPACTO FISIOPATOLOGICO Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia, Subprograma Estatal de Generación de Conocimiento. Francesc Villarroya Gombau. (Universitat de Barcelona). 01/01/2016-13/12/2017. 45.000 €. Team member.
6 PI13/00314, ESTUDIO DEL PAPEL DE LOS TRANSCRITOS DE BSCL2 EN LA ADIPOGENESIS Y NEUROGENESIS Convocatoria y ayudas de la Acción Estratégica en Salud 2013-ISCIII. David Araujo Vilar. (Complejo Hospitalario Universitario de Santiago compostela). 01/01/2014-31/12/2016. 68.365 €. Co-ordinator.
7 GPC2014/036, PROGRAMA DE CONSOLIDACIÓN E ESTRUTURACIÓN DE UNIDADES DE INVESTIGACIÓN COMPETITIVAS PROGRAMA DE CONSOLIDACIÓN E ESTRUTURACIÓN DE UNIDADES DE INVESTIGACIÓN COMPETITIVAS. David Araujo Vilar. (Universidad de Santiago de Compostela). 2014-2016. 70.000 €.
8 Estudio de los mecanismos moleculares de la Encefalopatía de Celia V convocatoria de Ayudas a la Investigación-Fundación MEHUER. David Araujo Vilar. (Universidad de Santiago de Compostela). 14/01/2014-31/12/2014. 6.000 €. Co-ordinator.
9 Efecto del PTC124 (Ataluren) sobre la adipogénesis en preadipocitos de pacientes con mutaciones sin sentido en el gen BSCL2 Diputación de A Coruña. Ayudas a la Investigación de la Diputación de A Coruña. David Araujo Vilar. (Universidad de Santiago de Compostela). 01/07/2012-31/07/2013. 7.500 €. Co-ordinator.
10 10PXIB208013PR, Un nuevo síndrome neurodegenerativo asociado a la mutación R329X en el gen BSCL2: Caracterización clínica y molecular XUNTA DE GALICIA. Plan galego de investigación, desenvolvemento e innovación tecnolóxica. David Araujo Vilar. (Universidad de Santiago de Compostela). 2010-2013. 68.000 €. Co-ordinator.
11 PS09/17, Estudio de la lipomatosis asociada a la lipodistrofia parcial familiar tipo 2 XUNTA DE GALICIA. Ayudas a la Investigación de la Consellería de Sanidade-Xunta de Galicia. Francisco Barreiro Morandeira. (Complejo Hospitalario Universitario de Santiago compostela). 01/10/2009-30/09/2011. 25.000 €. Co-ordinator.

12 PI081449, Correlacion fenotipo-genotipo y bases moleculares de la lipodistrofia parcial familiar Instituto de Salud Carlos III. Acción Estratégica de Salud. David Araujo Vilar. (COMPLEJO HOSPITALARIO SANTIAGO DE COMPOSTELA). 2009-2011. 102.850 €. Co-ordinator.

13 IN845B-2010/033, Consolidación e estruturación das unidades de investigación do sistema galego de I+D+I. Grupos de investigación XUNTA DE GALICIA. consolidación e a estruturacion de unidades de investigación competitivas do sistema galego de I+D+I. Joaquín Lado Abeal. (Universidad de Santiago de Compostela). 01/01/2010-17/12/2010. 22.400 €. Team member.

14 INCITE09E1R208068ES, Consolidación e estruturación de unidades de investigación (UETeM) XUNTA DE GALICIA. consolidación e estruturación de unidades de investigación competitivas do sistema galego de I+D+I. David Araujo Vilar. (Universidad de Santiago de Compostela). 01/01/2009-11/12/2009. 55.318,24 €.

15 SAF2009-05555-E, INTERNATIONAL MEETING ON FAMILIAL LIPODYSTROPHIES Ministerio de Ciencia e Innovación. Acciones Complemetarias-Ministerio de Ciencia e Innovación. David Araujo Vilar. (Universidad de Santiago de Compostela). 03/04/2009-04/04/2009. 2.500 €. Co-ordinator.

16 Influencia de la adipogénesis regional sobre los determinantes de riesgo cardiovascular en mujeres post- menopáusicas: Una aproximación fenómica" al síndrome metabólico. Fundación Pfizer. Premios a la Investigación en Salud de la Mujer. David Araujo Vilar. (Universidad de Santiago de Compostela). 2008-2009. 10.000 €. Co-ordinator.

17 PGIDIT06PXIB208360PR, Identificación de mecanismos moleculares asociados al desarrollo del síndrome del enfermo eutiroideo en la anorexia nerviosa XUNTA DE GALICIA. Programa de Promoción Xeral de Investigación. Joaquín Lado Abeal. (Universidad de Santiago de Compostela). 2006-2009. 80.000 €. Team member.

18 BASES MOLECULARES DE LA LIPOMATOSIS ASOCIADA A LA LIPODISTROFIA PARCIAL FAMILIAR Y SU POSIBLE RELACION CON EL CANCER DE COLON Fundación Mutua Madrileña. David Araujo Vilar. (COMPLEJO HOSPITALARIO SANTIAGO DE COMPOSTELA). 2008-2008. 20.000 €. Co-ordinator.

19 PI030420, Estudio de la prevalencia y mecanismos de acción de mutaciones en el receptor de TSH y subunidad alfa de la proteína Gs en bocios multinodulares tóxicos y adenomas tóxicos en la Comunidad Autónoma de Galicia. Instituto de Salud Carlos III. Programa de Promocion de la Investigacion Biomedica y en Ciencias de la Salud. Joaquín Lado Abeal. (Universidad de Santiago de Compostela). 2003-2006. 145.015 €. Team member.

20 PGIDIT03PXIB20801PR, Mecanismos moleculares que determinan la distribucion de la grasa corporal y su influencia en el desarrollo de resistencia a la insulina en dos modelos, el síndrome de Dunnigan y el hipercortisolismo crónico Programa de Promoción Xeral de Investigación. David Araujo Vilar. (Universidad de Santiago de Compostela). 2003-2006. 45.000 €. Co-ordinator.

C.3. Participation in R&D and Innovation contracts

Lipodystrophy-Connect Bristol-Myers Squibb-NIH. Kyle Brown. 01/10/2013-01/10/2018. 100.000 €.

C.4. Patents

David Araújo Vilar; Carlos Alberto Rega Lista; José Cebezas Cerrato. 1936. Stellum-MMg. Programa para la cuantificación de la sensibilidad periférica a la insulina Spain. 1998. Universidad de Santiago de Compostela.